

Mentice has received a \$630,000 USD order for simulation solutions from a top 20 global MedTech company.

Mentice (publ), Gothenburg, a globally recognized leader in simulation solutions for image-guided interventional therapies, announced today that it has secured a significant order from a top 20 global Med Tech company, a long-standing customer of Mentice.

The order includes 12 VIST Mini simulators to expand the company's U.S. imaging training program, along with a comprehensive upgrade to its existing ICE (Intracardiac Echocardiography) imaging software. The technology is designed to enhance procedural precision, reduce patient radiation exposure, and minimize the need for general anesthesia.

As ICE imaging becomes increasingly important in structural heart procedures, Mentice's simulation technology will serve as a key platform for one of the major players in this field. The company anticipates further large-scale orders from global markets, driven by the growing adoption of ICE imaging by physicians worldwide.

Göran Malmberg, CEO of Mentice, commented, "We are proud to strengthen our collaboration with a leading company in the medical technology field. This order reflects the continued trust in Mentice's technology to support physicians in delivering safer, more effective patient care."

This latest order underscores Mentice's role as a trusted partner for the world's leading healthcare innovators, providing advanced simulation solutions that enhance clinical outcomes.

The order will be accounted for in the order book for the business area of the Medical Device Industry during the fourth quarter of 2024. These orders are anticipated to be delivered during the fourth quarter and the beginning of 2025.

Source:

- Mentice definition of a Top 20 Medical Technology company can be found here: <https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html>
- The growing adoption of intracardiac echocardiography (ICE) is highlighted in the following publications: ([Mayo Clinic News Network](#)), ([NeuroNews International](#)), ([SpringerLink](#)).

For more information, please contact:

Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-22 11:30 CEST.

Attachments

[Mentice has received a \\$630,000 USD order for simulation solutions from a top 20 global MedTech company.](#)